skip to content
Infliximab versus methotrexate, etanercept, adalimumab, and ustekinumab for plaque psoriasis : a review of the comparative clinical efficacy, safety and cost effectiveness Preview this item
ClosePreview this item
Checking...

Infliximab versus methotrexate, etanercept, adalimumab, and ustekinumab for plaque psoriasis : a review of the comparative clinical efficacy, safety and cost effectiveness

Author: Canadian Agency for Drugs and Technologies in Health.
Publisher: [Ottawa, Ont.] : Canadian Agency for Drugs and Technologies in Health, 2012.
Series: Rapid response report.
Edition/Format:   eBook : Document : English
Summary:
According to large-scale population studies conducted in the United Kingdom in 2006, psoriasis affects 1.5% of individuals and if these prevalence rates are apply to the Canadian population, more than 500,000 Canadians could be diagnosed with psoriasis. The most common clinical form of psoriasis is plaque psoriasis, encompassing approximately 80% of psoriasis patients. There are a variety of management options for  Read more...
Rating:

(not yet rated) 0 with reviews - Be the first.

Subjects
More like this

Find a copy online

Links to this item

Find a copy in the library

&AllPage.SpinnerRetrieving; Finding libraries that hold this item...

Details

Genre/Form: Electronic books
Material Type: Document, Internet resource
Document Type: Internet Resource, Computer File
All Authors / Contributors: Canadian Agency for Drugs and Technologies in Health.
OCLC Number: 818083737
Notes: "30 July 2012."
Description: 1 online resource (25 pages) : tables, digital file.
Contents: Pages:1 to 8; Pages:9 to 16; Pages:17 to 24; Pages:25 to 25.
Series Title: Rapid response report.
Responsibility: [prepared by Canadian Agency for Drugs and Technologies in Health].
More information:

Abstract:

According to large-scale population studies conducted in the United Kingdom in 2006, psoriasis affects 1.5% of individuals and if these prevalence rates are apply to the Canadian population, more than 500,000 Canadians could be diagnosed with psoriasis. The most common clinical form of psoriasis is plaque psoriasis, encompassing approximately 80% of psoriasis patients. There are a variety of management options for psoriasis, but no permanent cure. Mild-to-moderate forms of psoriasis are treated with topical therapy and phototherapy, while moderate-to-severe forms (PASI score?10) require systemic or biologic therapy. These therapies include: the disease-modifying anti-rheumatic drug, methotrexate; the tumor necrosis factor-alpha (TNF-[alpha]) blockers, adalimumab, etanercept, and infliximab; and the inhibitor of interleukin (IL)-12 and IL-23, ustekinumab. Infliximab has been recommended for the treatment of adults with very severe plaque psoriasis that have failed to respond to standard therapies such as methotrexate, cyclosporine, or ultraviolet radiation, or are intolerant to these treatments. The purpose of this review is to examine the comparative clinical efficacy, safety, and cost-effectiveness of infliximab versus methotrexate, etanercept, adalimumab, or ustekinumab for the treatment of adults with plaque psoriasis.

Reviews

User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

Be the first.
Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Linked Data


Primary Entity

<http://www.worldcat.org/oclc/818083737> # Infliximab versus methotrexate, etanercept, adalimumab, and ustekinumab for plaque psoriasis : a review of the comparative clinical efficacy, safety and cost effectiveness
    a schema:MediaObject, schema:Book, schema:CreativeWork ;
    library:oclcnum "818083737" ;
    library:placeOfPublication <http://id.loc.gov/vocabulary/countries/onc> ;
    library:placeOfPublication <http://experiment.worldcat.org/entity/work/data/2258082353#Place/ottawa_ont> ; # Ottawa, Ont.
    schema:about <http://experiment.worldcat.org/entity/work/data/2258082353#Topic/antibodies_monoclonal_therapeutic_use> ; # Antibodies, Monoclonal--therapeutic use
    schema:about <http://dewey.info/class/616.526061/e20/> ;
    schema:about <http://experiment.worldcat.org/entity/work/data/2258082353#Topic/psoriasis_chemotherapy_evaluation> ; # Psoriasis--Chemotherapy--Evaluation
    schema:about <http://experiment.worldcat.org/entity/work/data/2258082353#Topic/recombinant_fusion_proteins_therapeutic_use> ; # Recombinant Fusion Proteins--therapeutic use
    schema:about <http://experiment.worldcat.org/entity/work/data/2258082353#Topic/anti_inflammatory_agents_therapeutic_use> ; # Anti-Inflammatory Agents--therapeutic use
    schema:about <http://experiment.worldcat.org/entity/work/data/2258082353#Topic/psoriasis_drug_therapy> ; # Psoriasis--drug therapy
    schema:about <http://experiment.worldcat.org/entity/work/data/2258082353#Topic/immunosuppressive_agents_therapeutic_use> ; # Immunosuppressive Agents--therapeutic use
    schema:about <http://experiment.worldcat.org/entity/work/data/2258082353#Topic/infliximab_therapeutic_use> ; # Infliximab--Therapeutic use
    schema:bookFormat schema:EBook ;
    schema:contributor <http://viaf.org/viaf/145374402> ; # Canadian Agency for Drugs and Technologies in Health.
    schema:datePublished "2012" ;
    schema:description "According to large-scale population studies conducted in the United Kingdom in 2006, psoriasis affects 1.5% of individuals and if these prevalence rates are apply to the Canadian population, more than 500,000 Canadians could be diagnosed with psoriasis. The most common clinical form of psoriasis is plaque psoriasis, encompassing approximately 80% of psoriasis patients. There are a variety of management options for psoriasis, but no permanent cure. Mild-to-moderate forms of psoriasis are treated with topical therapy and phototherapy, while moderate-to-severe forms (PASI score?10) require systemic or biologic therapy. These therapies include: the disease-modifying anti-rheumatic drug, methotrexate; the tumor necrosis factor-alpha (TNF-[alpha]) blockers, adalimumab, etanercept, and infliximab; and the inhibitor of interleukin (IL)-12 and IL-23, ustekinumab. Infliximab has been recommended for the treatment of adults with very severe plaque psoriasis that have failed to respond to standard therapies such as methotrexate, cyclosporine, or ultraviolet radiation, or are intolerant to these treatments. The purpose of this review is to examine the comparative clinical efficacy, safety, and cost-effectiveness of infliximab versus methotrexate, etanercept, adalimumab, or ustekinumab for the treatment of adults with plaque psoriasis."@en ;
    schema:description "Pages:1 to 8; Pages:9 to 16; Pages:17 to 24; Pages:25 to 25."@en ;
    schema:exampleOfWork <http://worldcat.org/entity/work/id/2258082353> ;
    schema:genre "Electronic books"@en ;
    schema:inLanguage "en" ;
    schema:isPartOf <http://experiment.worldcat.org/entity/work/data/2258082353#Series/rapid_response_report> ; # Rapid response report.
    schema:isPartOf <http://experiment.worldcat.org/entity/work/data/2258082353#Series/rapid_response_report_summary_with_critical_appraisal> ; # Rapid response report, summary with critical appraisal
    schema:name "Infliximab versus methotrexate, etanercept, adalimumab, and ustekinumab for plaque psoriasis : a review of the comparative clinical efficacy, safety and cost effectiveness"@en ;
    schema:productID "818083737" ;
    schema:publication <http://www.worldcat.org/title/-/oclc/818083737#PublicationEvent/ottawa_ont_canadian_agency_for_drugs_and_technologies_in_health_2012> ;
    schema:publisher <http://experiment.worldcat.org/entity/work/data/2258082353#Agent/canadian_agency_for_drugs_and_technologies_in_health> ; # Canadian Agency for Drugs and Technologies in Health
    schema:url <http://proxy.library.carleton.ca/login?url=http://books.scholarsportal.info/viewdoc.html?id=/ebooks/ebooks1/gibson_chrc/2012-11-25/1/10611082> ;
    schema:url <http://site.ebrary.com/id/10611082> ;
    schema:url <http://public.eblib.com/choice/publicfullrecord.aspx?p=3282759> ;
    schema:url <http://www.deslibris.ca/ID/234391> ;
    wdrs:describedby <http://www.worldcat.org/title/-/oclc/818083737> ;
    .


Related Entities

<http://experiment.worldcat.org/entity/work/data/2258082353#Agent/canadian_agency_for_drugs_and_technologies_in_health> # Canadian Agency for Drugs and Technologies in Health
    a bgn:Agent ;
    schema:name "Canadian Agency for Drugs and Technologies in Health" ;
    .

<http://experiment.worldcat.org/entity/work/data/2258082353#Series/rapid_response_report> # Rapid response report.
    a bgn:PublicationSeries ;
    schema:hasPart <http://www.worldcat.org/oclc/818083737> ; # Infliximab versus methotrexate, etanercept, adalimumab, and ustekinumab for plaque psoriasis : a review of the comparative clinical efficacy, safety and cost effectiveness
    schema:name "Rapid response report." ;
    .

<http://experiment.worldcat.org/entity/work/data/2258082353#Series/rapid_response_report_summary_with_critical_appraisal> # Rapid response report, summary with critical appraisal
    a bgn:PublicationSeries ;
    schema:hasPart <http://www.worldcat.org/oclc/818083737> ; # Infliximab versus methotrexate, etanercept, adalimumab, and ustekinumab for plaque psoriasis : a review of the comparative clinical efficacy, safety and cost effectiveness
    schema:name "Rapid response report, summary with critical appraisal" ;
    .

<http://experiment.worldcat.org/entity/work/data/2258082353#Topic/anti_inflammatory_agents_therapeutic_use> # Anti-Inflammatory Agents--therapeutic use
    a schema:Intangible ;
    schema:name "Anti-Inflammatory Agents--therapeutic use"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/2258082353#Topic/antibodies_monoclonal_therapeutic_use> # Antibodies, Monoclonal--therapeutic use
    a schema:Intangible ;
    schema:name "Antibodies, Monoclonal--therapeutic use"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/2258082353#Topic/immunosuppressive_agents_therapeutic_use> # Immunosuppressive Agents--therapeutic use
    a schema:Intangible ;
    schema:name "Immunosuppressive Agents--therapeutic use"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/2258082353#Topic/psoriasis_drug_therapy> # Psoriasis--drug therapy
    a schema:Intangible ;
    schema:name "Psoriasis--drug therapy"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/2258082353#Topic/recombinant_fusion_proteins_therapeutic_use> # Recombinant Fusion Proteins--therapeutic use
    a schema:Intangible ;
    schema:name "Recombinant Fusion Proteins--therapeutic use"@en ;
    .

<http://viaf.org/viaf/145374402> # Canadian Agency for Drugs and Technologies in Health.
    a schema:Organization ;
    schema:name "Canadian Agency for Drugs and Technologies in Health." ;
    .

<http://www.worldcat.org/title/-/oclc/818083737>
    a genont:InformationResource, genont:ContentTypeGenericResource ;
    schema:about <http://www.worldcat.org/oclc/818083737> ; # Infliximab versus methotrexate, etanercept, adalimumab, and ustekinumab for plaque psoriasis : a review of the comparative clinical efficacy, safety and cost effectiveness
    schema:dateModified "2018-07-13" ;
    void:inDataset <http://purl.oclc.org/dataset/WorldCat> ;
    .


Content-negotiable representations

Close Window

Please sign in to WorldCat 

Don't have an account? You can easily create a free account.